Business Wire

Hytera Mission-critical Push-to-talk Solution Wins Flagship Industry Award

25.5.2023 18:29:00 EEST | Business Wire | Press release

Share

Hytera Communications (SZSE: 002583), a leading global provider of professional communications technologies and solutions, received the award of “Best use of critical communications in utilities” with its entry “LECO Electricity MCPTT” at the International Critical Communications Awards (ICCAs) 2023 ceremony held in Helsinki, Finland on May 23. The ICCAs, presented by the Critical Communications Association (TCCA), is a highly-anticipated program recognizing the success of products, organizations, and individuals that have pushed boundaries and capabilities within the field of critical communications. Earlier in April, Hytera’s seven entries were shortlisted by ICCAs.

This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20230525005622/en/

To view this piece of content from mms.businesswire.com, please give your consent at the top of this page.

Tony Gray, former CEO of TCCA, presenting the ICCA award to Hytera representative (on the right) (Photo: Business Wire)

This Mission-critical Push-to-talk (MCPTT) deployment highlights a clear path for the migration of the private communications network in the utility sector. Working with local partner Dialog Enterprise, Hytera has deployed a customized MCPTT system for LECO, Lanka Electricity Company (Private) Limited. As the rapid-response arm of the Ceylon Electricity Board, LECO provides electrical services to underserved areas and now works with a state-of-the-art radio communications system based on MCPTT over 4G-LTE technology to cover service grids in Galle, Moratuwa, Kalutara, Negombo, Kelaniya, Kotte, and Nugegoda. In the extreme scenario where cellular network coverage is not available, Hytera’s dual-mode rugged radios support device-to-device (D2D) communication empowered by Digital Mobile Radio (DMR) technology. While it proves the versatility of MCPTT to serve utility companies, the project also demonstrates how product innovations, such as dual-mode radios, can win the users’ buy-ins in technology adoption.

“This MCPTT solution operates at a higher priority than Internet services, and also having a device-to-device communication mode are huge pluses for LECO,” said Athula P. De Silva, Chairman of LECO. “Because when connectivity is interrupted due to unforeseeable circumstances–like a sudden violent storm, for instance–we are the professionals whose job it is to bring the network back up. With this, our dispatchers and field engineers are in constant touch since we are in complete control of our own internal communication channel. So, in the event of an outage, power can be restored much faster. If we had chosen the generic mobile voice service or Push-to-talk over Cellular (PoC) instead, our rapid response team’s communications would have been vulnerable to the same disruptive factors and service interruptions as the general public–and that was totally unacceptable. We are the first line of defense against power outages. MCPTT solution is a perfect fit for our requirements.”

Hytera HyTalk MC Mission Critical Services (MCS) system is a multimedia mission-critical communication solution designed for sectors such as public safety, utilities, and transportation. It is fully compliant with the 3GPP MC standards including MCPTT, MCData, and MCVideo. It delivers reliable voice and video communication, high-speed data transfer, and multimedia dispatch services for daily operations. It helps enhance connectivity for better collaboration and improved situational awareness.

Priority Quality of Service (QoS) of HyTalk MC is guaranteed on the servers of the MCPTT platform provider and on the mobile operator's network. This end-to-end QoS ensures that critical communications users are given the highest priority available over any other commercial users. HyTalk MC also enables Professional Mobile Radio (PMR) to LTE interoperability, so that it allows connections among different task forces.

“The award is a great recognition to all the stakeholders of this project, including LECO and Dialog. This case epitomizes how technological advancements are introduced and adopted to empower professionals from the utility sector,” said Ming Kam Wong, deputy GM of Hytera overseas business, who was present at the ICCAs ceremony. “Hytera is humbled to see itself becoming a frequent participant and winner of ICCAs. Thank you to the panel and congratulations to all the winners of ICCAs 2023.”

About Hytera

Hytera Communications Corporation Limited (SZSE: 002583) is a leading global provider of professional communications technologies and solutions. With voice, video and data capabilities, we provide faster, safer, and more versatile connectivity for business and mission critical users. We make the world more efficient and safer by enabling our customers to achieve more in both daily operations and emergency response. Learn more at https://www.hytera.com/en/home.html.

To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.

Contact information

lele.yao@hytera.com

About Business Wire

For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.

Subscribe to releases from Business Wire

Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from Business Wire

International Human Rights Lawyer Jared Genser and Former White House Counsel Lanny J. Davis Join Legal and Advocacy Team Supporting Cambodian Businessman Yim Leak, Seiden Law LLP Announces18.9.2026 20:52:00 EEST | Press release

International human rights lawyer Jared Genser and Lanny J. Davis, who has close ties to two former US presidents and a worldwide reputation for defending those under attack with lies and smears, and for repairing the damage done to their reputations, have joined the legal and advocacy team supporting Cambodian businessman Yim Leak, Seiden Law LLP, which serves as Yim Leak's chief global counsel, announced today. Their first move is to hold the Thai government accountable, framing its conduct as either complicit in or willfully blind to a sustained smear campaign against Yim. Genser is Managing Director of Perseus Strategies, an international law firm. Over more than two decades, he has served as pro bono counsel to five Nobel Peace Prize laureates. The New York Times has referred to him as "The Extractor" for his work freeing political prisoners worldwide. Genser's decision to support Yim Leak's team comes as the businessman faces an asset freeze exceeding 20 billion baht (more than U

Ningbo FEED Meeting Confirms Full Confidence in Q1 2027 FID for Allied Biofuels’ US$6.1 Billion Presidential Decree-Backed SAF and e-SAF Project18.9.2026 18:38:00 EEST | Press release

Allied Biofuels has held a major Front-End Engineering Design (FEED) meeting at Sinopec’s office in Ningbo, China, bringing together Allied Biofuels, Sinopec Engineering Group Co., Ltd. of China, Topsoe A/S of Denmark, Sasol South Africa Limited, and Plug Power of the United States — the principal international engineering and technology providers supporting its US$6.1 billion Presidential Decree-backed Sustainable Aviation Fuel (SAF) and e-SAF project in Uzbekistan. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260918708077/en/ FEED Meeting - Ningbo, China At the joint FEED meeting of the project’s core engineering and technology stakeholders, the discussions established clear alignment on engineering responsibilities, technology interfaces, design deliverables, project integration and the coordinated execution programme required to advance the project through FEED. All stakeholders working on the project expressed full co

Corcept Announces CHMP Opinion Recommending EU Marketing Authorization for Lifyorli ® (Relacorilant)18.9.2026 15:00:00 EEST | Press release

Corcept Therapeutics Incorporated (NASDAQ: CORT), a commercial-stage company engaged in the discovery and development of medications to treat severe endocrinologic, oncologic, metabolic and neurologic disorders by modulating the effects of the hormone cortisol, today announced that the European Medicines Agency’s Committee for Medicinal Products for Human Use (CHMP) has recommended that the European Commission (EC) should approve relacorilant, combined with the chemotherapy drug nab-paclitaxel, for the treatment of patients with platinum-resistant ovarian cancer. The CHMP’s recommendation is based on positive data from Corcept’s Phase 2 and pivotal Phase 3 ROSELLA trials, in which patients receiving relacorilant combined with nab-paclitaxel experienced improved progression-free and overall survival compared to patients who received nab-paclitaxel alone. The safety profile of relacorilant plus nab-paclitaxel in these trials was consistent with the safety profile of nab-paclitaxel monoth

Enhertu ® Recommended for Approval in the EU by CHMP as Adjuvant Treatment for Patients with Residual Disease After Neoadjuvant Treatment for HER2 Positive Early Breast Cancer18.9.2026 15:00:00 EEST | Press release

Enhertu® (trastuzumab deruxtecan) has been recommended for approval in the European Union (EU) as a monotherapy for the adjuvant treatment of adult patients with resected HER2 positive breast cancer who have residual invasive disease after neoadjuvant taxane-based and HER2 targeted treatment. Enhertu is a specifically engineered HER2 directed DXd antibody drug conjugate (ADC) discovered by Daiichi Sankyo (TSE: 4568) and being jointly developed and commercialized by Daiichi Sankyo and AstraZeneca (LSE/STO/NYSE: AZN). The Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) based its positive opinion on results from the DESTINY-Breast05 phase 3 trial presented at the 2025 European Society for Medical Oncology (#ESMO25) Congress and subsequently published in The New England Journal of Medicine. The recommendation will now be reviewed by the European Commission, which has the authority to grant marketing authorizations for medicines in the EU. In DES

CHMP Recommends EU Approval of New Indication for Alfasigma’s Jyseleca ® (filgotinib), Treatment of Adults With Axial Spondyloarthritis18.9.2026 13:58:00 EEST | Press release

Alfasigma S.p.A, a global pharmaceutical company with a focus on innovation in rare disease and specialty care in areas where there is significant unmet patient need, today announced that the European Medicines Agency’s (EMA) Committee for Medicinal Products for Human Use (CHMP) has issued a positive opinion for Jyseleca® (filgotinib), an oral, once-daily JAK1 preferential inhibitor, for the treatment of patients with active axial spondyloarthritis (axSpA), both non-radiographic and radiographic forms of the disease, who have responded inadequately to conventional therapy. Following this positive opinion, the application is now referred to the European Commission (EC) for final action. The EC’s decision is expected in the next weeks. “At present, half of people living with axSpA fail to adequately respond to treatment, leaving them with years of preventable struggle with persistent pain and other impactful symptoms,” said Daniele D'Ambrosio, Chief Development Officer, Alfasigma. “This

In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.

Visit our pressroom
World GlobeA line styled icon from Orion Icon Library.HiddenA line styled icon from Orion Icon Library.Eye